Biogen ' s Abandonment of AD Drug No Surprise, Experts Say Biogen ' s Abandonment of AD Drug No Surprise, Experts Say

More than 2 years after its controversial accelerated FDA approval, Biogen says it will halt development and commercialization of aducanumab and focus on lecanemab.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery Source Type: news